Magnolia Capital Advisors LLC Alaunos Therapeutics, Inc. Transaction History

Magnolia Capital Advisors LLC

$194 Million
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	SELL	$0.04 - $0.13 $1,258 - $4,090	-31,462 Reduced 7.27%	401,507 $28,000
Q3 2023 Nov 03, 2023	BUY	$0.12 - $0.5 $51,956 - $216,484	432,969 New	432,969 $56,000
Q1 2023 May 15, 2023	BUY	$0.46 - $0.81 $10,879 - $19,156	23,650 Added 5.57%	448,469 $282,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $261.0 $3,125 - $1.63 Million	6,250 Added 1.49%	424,819 $276,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $87,269 - $27.1 Million	83,913 Added 25.07%	418,569 $720,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $1.24 $61,171 - $185,008	149,200 Added 80.45%	334,656 $414,000
Q1 2022 May 16, 2022	BUY	$0.62 - $1.17 $39,060 - $73,710	63,000 Added 51.45%	185,456 $121,000
Q4 2021 Jan 26, 2022	BUY	$1.09 - $1.89 $20,946 - $36,320	19,217 Added 18.61%	122,456 $133,000
Q3 2021 Nov 10, 2021	BUY	$1.44 - $2.73 $7,704 - $14,605	5,350 Added 5.47%	103,239 $188,000
Q2 2021 Jul 29, 2021	BUY	$2.63 - $3.67 $257,448 - $359,252	97,889 New	97,889 $258,000
Q1 2021 May 14, 2021	SELL	$2.82 - $5.6 $247,494 - $491,478	-87,764 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$2.09 - $3.09 $183,004 - $270,566	87,562 Added 43347.52%	87,764 $221,000
Q3 2020 Nov 02, 2020	SELL	$2.39 - $3.43 $191,529 - $274,873	-80,138 Reduced 99.75%	202 $202,000
Q3 2020 Nov 02, 2020	SELL	$2.39 - $3.43 $24,485 - $35,140	-10,245 Reduced 11.31%	80,340 $202,000
Q2 2020 Jul 30, 2020	SELL	$2.2 - $3.71 $2,420 - $4,081	-1,100 Reduced 1.2%	90,585 $297,000
Q1 2020 Apr 14, 2020	SELL	$1.9 - $4.98 $16,074 - $42,130	-8,460 Reduced 8.45%	91,685 $225,000
Q4 2019 Mar 31, 2020	BUY	$3.95 - $5.35 $395,572 - $535,775	100,145 New	100,145 $472,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Magnolia Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Magnolia Capital Advisors LLC with notifications on news.

Account